Nilotinib
Anatomic Stage III Breast Cancer AJCC v8
National Cancer Institute (NCI)Small moleculePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
21 Active assets in the Anatomic Stage III Breast Cancer AJCC v8 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PANITUMUMAB National Cancer Institute (NCI) | Phase 2 | BB |
5-azacytidine City of Hope Medical Center | Phase 2 | BB |
Gdc-0449 OHSU Knight Cancer Institute | Phase 2 | B |
Perflutren Lipid Microsphere Intravenous Suspension UNC Lineberger Comprehensive Cancer Center | Phase 2/3 | B |
ALECTINIB OHSU Knight Cancer Institute | Phase 2 | B |
View all 27 →
Same molecule, other indications
Nilotinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BBB
Indicative ·
74 / 100
View asset →blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
70 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →